Greedy Insider
KNSA Insider Trades and Greediness Scores
Kiniksa Pharmaceuticals International, plc (KNSA) insider trades: since Nov 26, 2025, Greedy Insider recorded 4 open-market buys and 52 sales on Form 4 from 8 insiders. The strongest recent filing scored 91 (Strong).
Who bought and who sold
Across the last 56 scoreable Form 4 transactions in KNSA, 4 were open-market purchases and 52 were sales. The table lists the most recent filings with each one's Greediness Score, so the structurally unusual trades are easy to spot first.
| Insider | Role | Type | Shares | Date | Score | ||
|---|---|---|---|---|---|---|---|
| Megna Michael R | CHIEF ACCOUNTING OFFICER | Sell | 4600.0 | 369380.0 | 2026-09-03 | 87 | View |
| Patel Sanj K | Chair | Sell | 15144.0 | 1200616.4 | 2026-09-01 | 71 | View |
| Ragosa Mark | CFO | Sell | 4404.0 | 349149.12 | 2026-09-01 | 78 | View |
| Moat Ross | COO | Sell | 4007.0 | 317674.97 | 2026-09-01 | 89 | View |
| Paolini John F. | CHIEF MEDICAL OFFICER | Sell | 4029.0 | 319419.12 | 2026-09-01 | 76 | View |
| Megna Michael R | CHIEF ACCOUNTING OFFICER | Sell | 5531.0 | 438497.7 | 2026-09-01 | 91 | View |
| Patel Sanj K | Chair | Sell | 15144.0 | 1200616.4 | 2026-09-01 | 71 | View |
| Cole G Bradley | Director | Sell | 3673.0 | 299092.38 | 2026-07-29 | 67 | View |
| Megna Michael R | CHIEF ACCOUNTING OFFICER | Buy | 279.0 | 9346.5 | 2026-07-15 | 54 | View |
| Paolini John F. | CHIEF MEDICAL OFFICER | Sell | 37327.0 | 1997741.0 | 2026-05-01 | 83 | View |
The strongest recent filing
Megna Michael R (CHIEF ACCOUNTING OFFICER) sold 5,531 shares of Kiniksa Pharmaceuticals International, plc on Sep 1, 2026, a filing that scored 91 (Strong). It scored Strong because a senior insider was trading and it was direct personal ownership. The score describes the filing, not future returns. This is not investment advice.
Cluster activity
A cluster buy is present: 5 insiders (Megna Michael R, Patel Sanj K, Ragosa Mark, Moat Ross) traded KNSA the same direction within a 7-day window. Shared conviction is a stronger structural signal than a lone trade.
How this compares with Kiniksa Pharmaceuticals International, plc's own history
Open-market buys make up 7% of the 56 scoreable KNSA transactions on record between Nov 26, 2025 and Sep 3, 2026. Comparing a filing with the company's own buy/sell mix is how you tell a routine disposal from an unusual accumulation.
Methodology and sources
Scores come from six published, user-adjustable factors (insider role, cluster activity, trade size versus the insider's own history, position impact, filing urgency, and direct versus indirect ownership). The score describes the filing, not future returns. This is not investment advice.
Key facts
- Scoreable Form 4 transactions on record: 56
- Open-market buys: 4
- Sales: 52
- Distinct insiders: 8
- Strongest recent Greediness Score: 91 (Strong)
Primary sources
Related
- Strongest filing
- KNSA in the live feed
- How the Greediness Score works
- What is a cluster buy?
- Form 4 transaction codes
The score describes the filing, not future returns. This is not investment advice.